Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice

Neurobiology of Aging

Volumn 33, Issue 4, 2012, Pages 825.e15-825.e24

  Minami, S Sakura ^a   Clifford, Thomas G ^a   Hoe, Hyang Sook ^a   Matsuoka, Yasuji ^a   Rebeck, G William ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

APP; A ; Fyn; Phosphorylation; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PROTEIN KINASE FYN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; COGNITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMOZYGOSITY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LEARNING; MALE; MAZE TEST; MOUSE; MUTATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; SPATIAL LEARNING; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE;

EID: 84856974150     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.05.014     Document Type: Article

References (34)

1. Bhaskar K., Hobbs G.A., Yen S.H., Lee G. Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. Neuropathol. Appl. Neurobiol 2010, 36:462-477.
2. Bierer L.M., Hof P.R., Purohit D.P., Carlin L., Schmeidler J., Davis K.L., Perl D.P. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch. Neurol 1995, 52:81-88.
3. Chin J., Palop J.J., Puoliväli J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci 2005, 25:9694-9703.
4. Chin J., Palop J.J., Yu G.Q., Kojima N., Masliah E., Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci 2004, 24:4692-4697.
5. Duyckaerts C., Delatour B., Potier M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009, 118:5-36.
6. Gómez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol 1997, 41:17-24.
7. Hirata-Fukae C., Li H.F., Hoe H.S., Gray A.J., Minami S.S., Hamada K., Niikura T., Hua F., Tsukagoshi-Nagai H., Horikoshi-Sakuraba Y., Mughal M., Rebeck G.W., LaFerla F.M., Mattson M.P., Iwata N., Saido T.C., Klein W.L., Duff K.E., Aisen P.S., Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res 2008, 1216:92-103.
8. Ho G.J., Hashimoto M., Adame A., Izu M., Alford M.F., Thal L.J., Hansen L.A., Masliah E. Altered p59Fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role. Neurobiol. Aging 2005, 26:625-635.
9. Hoe H.S., Minami S.S., Makarova A., Lee J., Hyman B.T., Matsuoka Y., Rebeck G.W. Fyn modulation of Dab1 effects on amyloid precursor protein and ApoE receptor 2 processing. J. Biol. Chem 2008, 283:6288-6299.
10. Hoe H.S., Rebeck G.W. Functional interactions of APP with the apoE receptor family. J. Neurochem 2008, 106:2263-2271.
11. Horikoshi Y., Sakaguchi G., Becker A.G., Gray A.J., Duff K., Aisen P.S., Yamaguchi H., Maeda M., Kinoshita N., Matsuoka Y. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem. Biophys. Res. Commun 2004, 319:733-737.
12. Hughes K., Nikolakaki E., Plyte S.E., Totty N.F., Woodgett J.R. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 1993, 12:803-808.
13. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wölfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Götz J. Dendritic Function of Tau Mediates Amyloid-beta Toxicity in Alzheimer's Disease Mouse Models. Cell 2010, 142:387-397.
14. King D.L., Arendash G.W., Crawford F., Sterk T., Menendez J., Mullan M.J. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav. Brain Res 1999, 103:145-162.
15. King G.D., Turner R.S. Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?. Exp. Neurol 2004, 185:208-219.
16. Lee G., Newman S.T., Gard D.L., Band H., Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci 1998, 111:3167-3177.
17. Lee G., Thangavel R., Sharma V.M., Litersky J.M., Bhaskar K., Fang S.M., Do L.H., Andreadis A., Van Hoesen G., Ksiezak-Reding H. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J. Neurosci 2004, 24:2304-2312.
18. Matsuoka Y., Picciano M., Malester B., LaFrancois J., Zehr C., Daeschner J.M., Olschowka J.A., Fonseca M.I., O'Banion M.K., Tenner A.J., Lemere C.A., Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol 2001, 158:1345-1354.
19. Morgan D. Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochem. Res 2003, 28:1029-1034.
20. Morris R.G., Garrud P., Rawlins J.N., O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982, 297:681-683.
21. Nishitomi K., Sakaguchi G., Horikoshi Y., Gray A.J., Maeda M., Hirata-Fukae C., Becker A.G., Hosono M., Sakaguchi I., Minami S.S., Nakajima Y., Li H.F., Takeyama C., Kihara T., Ota A., Wong P.C., Aisen P.S., Kato A., Kinoshita N., Matsuoka Y. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J. Neurochem 2006, 99:1555-1563.
22. Nunan J., Small D.H. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett 2000, 483:6-10.
23. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 2003, 24:1063-1070.
24. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
25. Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D.H., LaFerla F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem 2006, 281:39413-39423.
26. Peña F., Ordaz B., Balleza-Tapia H., Bernal-Pedraza R., Márquez-Ramos A., Carmona-Aparicio L., Giordano M. Beta-amyloid protein (25-35) disrupts hippocampal network activity: role of Fyn-kinase. Hippocampus 2010, 20:78-96.
27. Planel E., Richter K.E., Nolan C.E., Finley J.E., Liu L., Wen Y., Krishnamurthy P., Herman M., Wang L., Schachter J.B., Nelson R.B., Lau L.F., Duff K.E. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J. Neurosci 2007, 27:3090-3097.
28. Roberson E.D., Halabisky B., Yoo J.W., Yao J., Chin J., Yan F., Wu T., Hamto P., Devidze N., Yu G.Q., Palop J.J., Noebels J.L., Mucke L. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci 2011, 31:700-711.
29. Shirazi S.K., Wood J.G. The protein tyrosine kinase, fyn, in Alzheimer's disease pathology. Neuroreport 1993, 4:435-437.
30. Stambolic V., Woodgett J.R. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem. J 1994, 303:701-704.
31. Suzuki T., Nakaya T. Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions. J. Biol. Chem 2008, 283:29633-29637.
32. Trojanowski J.Q., Lee V.M. Paired helical filament tau in Alzheimer's disease. The kinase connection. Am. J. Pathol 1994, 144:449-453.
33. Venkitaramani D.V., Chin J., Netzer W.J., Gouras G.K., Lesne S., Malinow R., Lombroso P.J. Beta-amyloid modulation of synaptic transmission and plasticity. J. Neurosci 2007, 27:11832-11837.
34. Zhang Y., Kurup P., Xu J., Carty N., Fernandez S.M., Nygaard H.B., Pittenger C., Greengard P., Strittmatter S.M., Nairn A.C., Lombroso P.J. Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc. Natl. Acad. Sci. U. S. A 2010, 107:19014-19019.